Bridgeway Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-51,600
| Closed | -$1.94M | – | 1433 |
|
|
2021
Q1 | $1.94M | Sell |
51,600
-79,900
| -61% | -$1.99M | 0.04% | 629 |
|
|
2020
Q4 | $2.24M | Hold |
131,500
| – | – | 0.05% | 486 |
|
|
2020
Q3 | $618K | Sell |
131,500
-35,000
| -21% | -$178K | 0.01% | 819 |
|
|
2020
Q2 | $1.02M | Buy |
166,500
+45,000
| +37% | +$185K | 0.02% | 649 |
|
|
2020
Q1 | $276K | Sell |
121,500
-25,000
| -17% | -$106K | 0.01% | 958 |
|
|
2019
Q4 | $672K | Buy |
146,500
+96,500
| +193% | +$382K | 0.01% | 852 |
|
|
2019
Q3 | $194K | Buy |
+50,000
| New | +$274K | ﹤0.01% | 1187 |
|
|
2017
Q2 | – | Sell |
-8,800
| Closed | -$318K | – | 1492 |
|
|
2017
Q1 | $318K | Buy |
+8,800
| New | +$388K | ﹤0.01% | 1196 |
|
|
2016
Q1 | – | Sell |
-5,000
| Closed | -$208K | – | 1497 |
|
|
2015
Q4 | $208K | Sell |
5,000
-35,000
| -88% | -$1.17M | ﹤0.01% | 1291 |
|
|
2015
Q3 | $616K | Hold |
40,000
| – | – | 0.01% | 935 |
|
|
2015
Q2 | $994K | Hold |
40,000
| – | – | 0.02% | 792 |
|
|
2015
Q1 | $914K | Sell |
40,000
-29,000
| -42% | -$732K | 0.02% | 818 |
|
|
2014
Q4 | $1.86M | Buy |
69,000
+10,000
| +17% | +$172K | 0.04% | 542 |
|
|
2014
Q3 | $692K | Buy |
59,000
+35,000
| +146% | +$442K | 0.02% | 926 |
|
|
2014
Q2 | $373K | Hold |
24,000
| – | – | 0.01% | 1203 |
|
|
2014
Q1 | $472K | Buy |
+24,000
| New | +$408K | 0.01% | 1103 |
|
Bridgeway Capital Management's FPRX Position: Q2 2021 in Review
Bridgeway Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 51,600 shares — an estimated $1.94M sold.
Bridgeway Capital Management first reported a position in FPRX in Q1 2014 and held it in 16 quarters. The position peaked at $2.24M in Q4 2020. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Bridgeway Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Bridgeway Capital Management sold 51,600 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $1.94M.
- Bridgeway Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q1 2014 and held it in 16 quarters.
- Bridgeway Capital Management's Five Prime Therapeutics, Inc. position peaked at $2.24M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Bridgeway Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.